Qiagen NV
$ 42.30
1.37%
07 Aug - close price
- Market Cap 8,724,375,000 USD
- Current Price $ 42.30
- High / Low $ 42.55 / 41.96
- Stock P/E 21.47
- Book Value 16.15
- EPS 1.97
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.12 %
- 52 Week High 54.44
- 52 Week Low 30.63
About
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Analyst Target Price
$45.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-04 | 2025-11-04 | 2025-08-05 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-07-31 | 2024-04-29 | 2024-02-06 | 2023-10-30 |
| Reported EPS | 0.62 | 0.54 | 0.62 | 0.64 | 0.63 | 0.58 | 0.64 | 0.62 | 0.6 | 0.5 | 0.6 | 0.56 |
| Estimated EPS | 0.6 | 0.54 | 0.62 | 0.62 | 0.63 | 0.54 | 0.65 | 0.59 | 0.56 | 0.47 | 0.6 | 0.54 |
| Surprise | 0.02 | 0 | 0 | 0.02 | 0 | 0.04 | -0.01 | 0.03 | 0.04 | 0.03 | 0 | 0.02 |
| Surprise Percentage | 3.3333% | 0% | 0% | 3.2258% | 0% | 7.4074% | -1.5385% | 5.0847% | 7.1429% | 6.383% | 0% | 3.7037% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jul 2026 | Jan 1970 | Jul 2025 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|
| Payment Date | 2026-07-14 | None | 2025-07-10 | None | None |
| Amount | $0.35 | $2.29 | $0.25 | $1.32 | $1.04 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QGEN
2026-08-08 07:40:52
QIAGEN N.V. (NYSE: QGEN) reported Q2 2026 net sales of $535.04 million and net income of $103.401 million, with diluted EPS of $0.50. The company executed a $496.7 million synthetic share repurchase in January 2026, reducing outstanding shares by 5.0%, and approved a $0.35 per share cash dividend for 2026. Operating cash flows for the first half of 2026 were $301.319 million, consistent with the prior year.
2026-08-08 07:40:52
QIAGEN N.V. has released a voting rights announcement per Article 40, Section 1 of the WpHG, following a notification from the AFM. The notification details that The Vanguard Group holds 2.92% of QIAGEN N.V.'s capital and voting rights as of July 30, 2026, corresponding to 6,045,368 ordinary shares. QIAGEN N.V. clarifies that it is not responsible for the accuracy of the notification, which was sourced from the AFM's public register.
2026-08-07 23:39:39
Qiagen N.V.'s average price target has been increased from $43.87 to $44.52 by 17 analysts, suggesting a 7% potential upside based on its closing price. The consensus rating remains a "Buy" from 22 covering analysts. Investors can explore more price target data and analyst recommendations on TradingView.
2026-08-07 19:39:39
QIAGEN N.V. has filed its Form 6-K Report of Foreign Private Issuer for the quarterly period ended June 30, 2026, with the United States Securities and Exchange Commission (SEC). The document is now accessible on QIAGEN's website. This release provides important capital market information for investors.
2026-08-07 19:39:39
Quantinno Capital Management LP significantly reduced its stake in Qiagen N.V. by 40.6% in the first quarter, now holding 132,392 shares valued at approximately $5.3 million. Despite this, Qiagen's recent quarterly earnings exceeded expectations, with EPS of $0.62 and revenue of $535 million, and the company reaffirmed its 2026 EPS outlook of $2.43. However, near-term revenue guidance for the third quarter and full year fell below analyst expectations, leading to a consensus "Hold" rating with an average price target of $42.43.
2026-08-07 19:39:39
QIAGEN N.V. exceeded its Q2 2026 EPS outlook with adjusted diluted EPS of $0.62, against an outlook of at least $0.60 CER, and reaffirmed its full-year 2026 guidance for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER. Despite a challenging operating environment and cautious capital spending, the company maintained high profitability and saw solid growth in its key pillars, particularly Sample technologies. QIAGEN also detailed advancements in AI-powered tools, automated workflows for TB detection, and expansion of its QIAcuity and QIAstat-Dx portfolios.
